PCNA、P16蛋白在卵巢癌组织中的表达及其临床价值的探讨  

Expressions of PCNA, P16 in ovarian tumor and their clinical significance

作　　者：袁碧波[1] 张士伟[1] 孙保存[2] 

机构地区：[1]天津医科大学总医院,300052 [2]天津医科大学病理教研室

出　　处：《现代妇产科进展》1999年第4期309-312,共4页Progress in Obstetrics and Gynecology

摘　　要：目的：研究PCNA、P16蛋白在卵巢癌中的表达及临床价值。方法：应用免疫组化法检测89份卵巢癌组织PCNA、P16蛋白的表达。结果：PCNA表达在上皮性，中、低分化以及晚期卵巢癌中的表达显著高于非上皮性，高分化及早期卵巢癌（P＜0．05），PCNA表达与残存癌灶大小、是否发生淋巴结转移无关（P＞0．05）。在晚期、残存癌灶≥2cm的卵巢癌中P16蛋白的表达明显低于早期、残存癌灶＜2cm者（P＜0．05）；P16蛋白表达与组织类型、组织分化、淋巴结有无转移无关（P＜0．05）。生存分析表明，PCNA、P16蛋白尚不能作为卵巢癌的独立预后因素。结论：肿瘤细胞的过度增殖在卵巢癌的发生、发展中起一定作用。P16蛋白表达的缺失与卵巢癌的进展有关。测定卵巢癌组织P16、PCNA的表达，对客观评价肿瘤的增殖状态，进行“个体化”治疗有指导价值。Objective To study the expressions of PCNA, P16 in ovarian tumor and their clinical significance. Methods: The expressions of PCNA, P16 were investigated in 89 cases of ovarian tumor (OT) by immunohistochemistry techniques. Results: The expression of PCNA in epithelial ovarian tumor (EOT)was higher than that in non-epithelial ovarian tumor(NEOT) (P<0. 05). In EOT group, the expression of PCNA in G2~G3 or advanced stage was higher than that in G1 or early stage (P<0.05). There were no relationship between expression of PCNA and residual carcinoma (RC) or lymphaden metastasis (LPM) (P>0. 05)and no differences between EOT and NEOT in expression of P16 protein (P>0.05). In EOT group,the expression of P16 protein in specimens from advanced stages or large RC (≥2cm) were significantly lower than those of early stages or small RC (<2cm). No relationship between expression of P16 and differentiation or lymphaden metastasis (LPM)was found (P>0. 05 ). Survival analysis revealed that PCNA and P16 could not be prognostic factors of ovarian tumor. Conclusions: The expressions of PCNA and P16 are very helpful in evaluating cell differentiation and may help us choose high risk patients and conduct'individual'therapy.

关 键 词：卵巢肿瘤 细胞增殖 增殖细胞核抗原 P16 治疗 

分 类 号：R737.31[医药卫生—肿瘤]